Literature DB >> 17617137

Prognostic significance of erythropoietin expression in human renal cell carcinoma.

Agniezka Michael1, Ekaterini Politi, Erik Havranek, Catherine Corbishley, Lena Karapanagiotou, Chris Anderson, Kate Relph, Konstantinos N Syrigos, Hardev Pandha.   

Abstract

OBJECTIVES: To investigate, in a retrospective study, the expression of erythropoietin (Epo) in human renal cell carcinoma (RCC) and its correlation with overall survival, as Epo (an haematopoietic cytokine that regulates the production of red blood cells), with its receptor, was recently localized in non-haematopoietic tissues, e.g. liver, uterus, central nervous system, vascular endothelial cells and solid tumours. PATIENTS AND METHODS: We used data from 113 patients who had radical nephrectomy for RCC between 1990 and 2000, taking sections from formalin-fixed and paraffin wax-embedded tissue blocks. The association between Epo staining and the patients' characteristics was assessed by either chi-squared tests (for categorical variables) or two-sample independent t-tests (for continuous variables).
RESULTS: Tissue from 37 patients (33%) was positive for cytoplasmic Epo expression; 76 (67%) samples were negative. Univariate hazard ratio analysis confirmed that those with positive Epo staining were more than twice as likely to die as those with negative staining (hazard ratio 2.34, 95% confidence interval 1.27-4.3).
CONCLUSION: This study shows that the expression of Epo in RCC is adversely associated with overall survival. This is the first report of such an association, and might be explained by the loss of Von Hippel-Lindau protein function in clear cell RCC. The expression of Epo might have potential use in clinical trials when stratifying high-risk patients for adjuvant therapy after nephrectomy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617137     DOI: 10.1111/j.1464-410X.2007.06978.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.

Authors:  Tania Romina Stoyanoff; Juan Pablo Rodríguez; Juan Santiago Todaro; Joaquín Diego Espada; Juan Pablo Melana Colavita; Nora Cristina Brandan; Adriana Mónica Torres; María Victoria Aguirre
Journal:  Tumour Biol       Date:  2016-07-28

2.  Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma.

Authors:  Keiichi Ito; Hidehiko Yoshii; Takako Asano; Akio Horiguchi; Makoto Sumitomo; Masamichi Hayakawa; Tomohiko Asano
Journal:  Exp Ther Med       Date:  2012-03-13       Impact factor: 2.447

3.  Successful treatment of erythropoietin-producing advanced renal cell carcinoma after targeted therapy using sunitinib: Case report and review of the literature.

Authors:  Kosuke Ueda; Shigetaka Suekane; Katsuaki Chikui; Makoto Nakiri; Fukuko Moriya; Tokumasa Hayashi; Jiro Miyajima; Kei Matsuoka
Journal:  Mol Clin Oncol       Date:  2012-08-03

4.  The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.

Authors:  Pengjie Wu; Ning Zhang; Xi Wang; Chi Zhang; Teng Li; Xianghui Ning; Kan Gong
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

5.  Unintentional Dual Benefit: Improvement in Secondary Polycythemia in a Patient Receiving Chemotherapy for Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Brooke Kania; Erinie Mekheal; Sherif Roman; Nader Mekheal; Vinod Kumar; Michael Maroules
Journal:  Eur J Case Rep Intern Med       Date:  2022-02-18

Review 6.  Functional significance of erythropoietin in renal cell carcinoma.

Authors:  Christudas Morais; David W Johnson; David A Vesey; Glenda C Gobe
Journal:  BMC Cancer       Date:  2013-01-10       Impact factor: 4.430

7.  Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.

Authors:  A Kapoor; A Gharajeh; A Sheikh; J Pinthus
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

8.  Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma.

Authors:  Daniel Beltrame Ferreira; Walter Henriques da Costa; Diego Abreu Clavijo; Ricardo Decia; Isabela Werneck Cunha; Luciana Schultz; Rafael Malagoli Rocha; Gustavo Cardoso Guimarães; Stênio de Cássio Zequi
Journal:  Kidney Cancer       Date:  2017-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.